Table 3 Ongoing clinical trials evaluating ICB therapies in dMMR/MSI-H tumors
Clinical trial | Phase | Drug treatment | Drugs | Tumor type | Current status |
|---|---|---|---|---|---|
NCT03150706 | II | Avelumab | Anti-PD-L1 mAb | Previously treated dMMR/MSI-H or POLE-mutated mCRC | Ongoing |
NCT03435107 | II | Durvalumab | Anti-PD-L1 mAb | Previously treated dMMR/MSI-H or POLE-mutated mCRC | Ongoing |
NCT02983578 | II | Durvalumab (MEDI4736) + AZD9150 | Anti-PD-L1 mAb + Antisense STAT3 | dMMR CRC, NSCLC, and advanced pancreatic cancer | Ongoing |
NCT02997228 | III | Atezolizumab + mFOLFOX6 + bevacizumab versus mFOLFOX6 + bevacizumab versus atezolizumab | Anti-PD-L1 mAb | dMMR mCRC | Ongoing |
NCT02912559 | III | Atezolizumab + standard chemotherapy* versus standard chemotherapy* | Anti-PD-L1 mAb | dMMR stage III resected CRC | Ongoing |
NCT03257163 | II | Pembrolizumab + capecitabine + radiation therapy | Anti-PD-1 mAb | dMMR and Epstein-Barr virus positive GC | Ongoing |
NCT02563002 | III | Pembrolizumab versus standard therapy** | Anti-PD-1 mAb | dMMR/MSI-H stage IV CRC | Not recruiting |
NCT03236935 | Ib | Pembrolizumab + L-NMMA | Anti-PD-1 mAb + nitric oxide synthase inhibitor | dMMR/MSI-H cancer, melanoma, NSCLC, HNSCC, classic HL, and urothelial carcinoma | Ongoing |
NCT03607890 | II | Nivolumab + relatlimab | Anti-PD-1 mAb + anti-LAG-3 mAb | MSI-H solid tumors refractory to prior PD-(L)1 therapy | Not recruiting |
NCT02992964 | I/II | Nivolumab | Anti-PD-1 mAb | Pediatric patients with hypermutant cancers, including biallelic MMR syndrome | Ongoing |
NCT03241745 | II | Nivolumab | Anti-PD-1 mAb | dMMR/MSI-H/hypermutated uterine cancer | Ongoing |
NCT02060188 | II | Nivolumab versus nivolumab + ipilimumab or nivolumab + ipilimumab + cobimetinib or nivolumab + BMS-986016 or nivolumab + daratumumab | Anti-PD-1 mAb + Anti-CTLA-4 mAb + MEK inhibitor + anti-LAG-3 mAb + anti-CD38 mAb | dMMR/pMMR/MSI-H/MSI-L/MSS CRC | Ongoing |